AI in pathology and dermatology: lung cancer biomarkers, Lunit–Summit, Mayo Clinic
AI-based pathology analysis shows promise for guiding lung cancer biomarker testing, and Summit Therapeutics is partnering with Lunit on AI pathology research. Mayo Clinic researchers assessed the Dermoscopy Explainable Intelligence AI for skin biopsy decisions, and breast cancer risk models also support nurse-led counselling.
Who is affected and how
- doctor
- Pathologists and dermatologists can evaluate AI as support for biomarker and biopsy decisions.
- pharmaceuticals
- AI pathology may also play a role in selecting patients for trials and in drug development.
Sources
- AI Analysis of Pathology Slides Shows Promise for Guiding Lung Cancer Biomarker Testing | Clinical Lab Productsclpmag.com · Oct 19, 2026
- AI Analysis of Pathology Slides Shows Promise for Guiding Lung Cancer Biomarker Testingclinical lab products · Oct 19, 2026
- AI digital pathology connects the cancer slide with treatment decisionsinnovation news network · Oct 19, 2026
- AI digital pathology connects the cancer slide with treatment decisions | Innovation News Networkinnovationnewsnetwork.com · Oct 19, 2026
- Summit Therapeutics partners with Lunit on AI pathology researchinvesting.com · Oct 23, 2026
- Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Developmentbusiness wire · Oct 23, 2026
- Mayo Clinic researchers assess AI for skin biopsy decisions — News-Medical - UA.NEWSua.news · Oct 23, 2026 · magyar
- AI Breast Cancer Risk Models Guide Triage and Nurse-Led Patient Counselingoncology nursing news · Oct 24, 2026
Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.